AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL.

美国犹他州福克斯，2024年5月1日/PRNewswire/--Biolexis Therapeutics，Inc.是一家临床阶段人工智能驱动的生物制药公司，今天宣布将于2024年5月3日至7日在伊利诺伊州芝加哥举行的2024年美国免疫学家协会（AAI）上发布最新海报。

The conference brings together the top immunology experts for in-depth discussions exploring a wide array of topics, highlighting the latest groundbreaking discoveries in the field. Biolexis' scientific team will be presenting pre-clinical data demonstrating the efficacy of the company's novel PIM1-inhibitor, BLX-0631..

会议汇集了顶级免疫学专家，深入讨论了广泛的主题，突出了该领域的最新突破性发现。Biolexis的科学团队将提供临床前数据，证明该公司新型PIM1抑制剂BLX-0631的功效。。

AAI poster presentation details are below:

AAI海报展示详情如下：

Title: 'Development of highly selective, potent, orally available PIM1 inhibitor BLX-0631 shows a therapeutics potential in Systemic Lupus Erythematosus (SLE) models'Session Title: Late-Breaking: Therapeutic Approaches to Autoimmunity (PM)Session Date and Time: Monday May 6, 2024, 2:15 PM - 3:30 PMLocation: Exhibit Hall F1Poster Board Number: B900Abstract ID: 6301.

标题：“开发高选择性，有效，口服可用的PIM1抑制剂BLX-0631在系统性红斑狼疮（SLE）模型中显示出治疗潜力”会议标题：迟发：自身免疫治疗方法（PM）会议日期和时间：2024年5月6日星期一下午2:15-下午3:30地点：展览厅F1海报板编号：B900摘要ID:6301。

More information can be found on the AAI meeting website.

更多信息可以在AAI会议网站上找到。

About Biolexis Therapeutics, Inc.Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, metabolic, neurodegenerative, auto-immune, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern™ AI-enabled drug discovery process..

关于Biolexis Therapeutics，Inc.Biolexis Therapeutics是一家私营临床阶段生物制药公司，致力于开发针对癌症，代谢，神经退行性疾病，自身免疫和炎症性疾病的小分子。Biolexis通过其专有的MolecuLern™AI支持的药物发现过程，以前所未有的速度和准确性迅速发现和开发新的临床候选药物。。

For more information, please visit www.biolexistx.com

有关更多信息，请访问www.biolexistx.com

SOURCE Biolexis Therapeutics Inc

SOURCE Biolexis Therapeutics Inc公司